Carb-X

Live Webinar: GARDP/REVIVE – Moving from preclinical to clinical-stage: Challenges and opportunities
2020-09-24 09:30 - 11:30 (America/New_York) | Webinar
Speakers:

Value of a pre-IND interaction with the US FDA during late lead optimization: Bugworks experience – Bala Subramanian, Bugworks Research Inc.
Amicidins: Building clinical and regulatory strategies for non-traditional products to prevent and treat life-threatening infections – Michael P. Bevilacqua, Amicrobe, Inc.
Discovery and development of microbiome therapeutics using reverse translation – Matthew Henn & Chris Ford, Seres
Therapeutics Development of a multi-component toxoid vaccine for S. aureus – Regulatory challenges and opportunities – M. Javad Aman & Catherine Bernard, Integrated BioTherapeutics
Regulatory challenges for RaPID/BSI – culture-free identification and characterization of bloodstream infections – David Steinmiller, HelixBind Inc.

Moderator: Erin Duffy, CARB-X
The presentation will be followed by a Q&A session.
Register now for this live webinar.

Antimicrobial Resistance Fighter Coalition Webinar: The global movement of microorganisms: Tracking the spread of difficult-to-treat infections
2020-09-24 09:00 - 10:00 | Webinar
AMR in the Light of COVID-19 – A Webinar Series
Each of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world.
About this Webinar:
Tracking the spread of COVID-19 has been critical to the global public health response. This information allows hospitals to prepare for surges, governments to deploy testing strategies, and citizens to modify their behavior appropriately. But while information about COVID-19 is readily and publicly available, the world still struggles to monitor and track the spread of drug resistant infections.How should global monitoring and data sharing evolve to combat antimicrobial resistance?
To learn more about the Antimicrobial Resistance Fighter Coalition, click here.
To learn more about this webinar series, click here.
To register for this webinar, click here.

ESCMID Conference on Coronavirus Disease (ECCVID)
2020-09-23 - 2020-09-25 | Webinar
Speakers include Kevin Outterson, Executive Director of CARB-X.
The ESCMID Conference on Coronavirus Disease (ECCVID) will take place online from Wednesday 23rd to Friday 25th September 2020 and will cover all aspects of COVID-19. ECCVID will feature a comprehensive scientific programme that will span a wide range of topics surrounding this emerging threat.
COVID-19 is a major public health incident which has brought about significant challenges and uncertainties with respect to diagnostics, therapeutics and infection prevention and control. We are learning continually about the new SARS-CoV-2 virus and an international scientific event that brings together the latest research and scientific evidence is very timely. ECCVID will offer excellent opportunities to showcase the latest findings, share experiences and knowledge and demonstrate practical techniques and guidance.
Internationally renowned clinical microbiologists, infectious diseases specialists and experts from related disciplines will present their work and latest findings on COVID-19, during the event.
Click here to learn more.
Click here to view the programme.
Click here to register.

Chatham House Webinar: Creating a New Generation of Antibiotics
2020-09-22 07:00 - 08:00 | Webinar
Participants include Kevin Outterson, Executive Director of CARB-X.
The world needs a new generation of antibiotics to address the rapid growth in antibiotic-resistant bacteria. The UK government’s 2014 Review on Antimicrobial Resistance estimated that such bacteria could result in the deaths of 10 million people a year by 2050 and an accumulated cost of up to $100 trillion to the global economy. Despite this urgent need, there remain few new antibiotics in development due to a lack of commercial viability for pharmaceutical companies with a 2019 Chatham House report highlighting the lack of progress being made on critical recommendations to tackle antimicrobial resistance.
This event will discuss the urgency of the development of new antibiotics and recent efforts to address the funding gap. What is the significance of the rise of antibiotic-resistant bacteria? What are the challenges at the intersection of increasing demand for new antibiotics and their commercial viability? Does the recent announcement of a new fund from the pharmaceutical industry represent a major shift, or just the beginning, of what is needed?
Participants:

Thomas Cueni, Director General, IFPMA
Jim O’Neill, Chair, Chatham House
Kevin Outterson, Associate Fellow, Global Health Programme, Chatham House
Laura Piddock, Professor of Microbiology; Deputy Director of the
Institute of Microbiology and Infection, University of Birmingham
Chair: Emma Ross, Senior Research Fellow, Global Health Programme, Chatham House

To learn more, click here.

Antimicrobial Resistance Fighter Coalition Webinar: Responding to difficult-to-treat infections: Role and responsibilities of governments, researchers, clinicians, industry and patients
2020-09-19 09:00 - 10:00 | Webinar
AMR in the Light of COVID-19 – A Webinar Series
Each of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world.
About this Webinar:
Governments, researchers, and industry partners around the world have mobilized to develop diagnostics, therapeutics, and vaccines for COVID-19. The development of new recommendations and practices continue to be deployed to slow the spread of COVID-19. The burden of drug-resistant infections could surpass COVID-19. Drugs like antibiotics are a vital tool for modern medicine, used to prevent and treat infections. As drug-resistant infections are becoming more common, modern medicine as we know it is at risk and much like COVID-19, it has the potential to overwhelm our healthcare structure. What changes are needed to reshape strategies for combatting antimicrobial resistance globally?
To learn more about the Antimicrobial Resistance Fighter Coalition, click here.
To learn more about this webinar series, click here.
To register for this webinar, click here.

Building, Funding, and Growing Successful Biotech Startups
2020-09-17 14:00 - 15:30 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers include Cameron Bess, Project Officer, Antibacterials Branch, Division of CBRN Medical Countermeasures, BARDA.
Turning a good scientific idea into a successful biotech startup is a challenging journey.This panel will highlight several successful paths that scientists can take toward creating a successful biotech company. Learn what New York-area resources are available to turn your idea into a business and help you develop entrepreneurial skills.
The event will introduce funding and strategic programs available from IndieBio, the Center for Biotechnology, the National Institutes of Health (NIH), and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Speakers include:

Anton Xavier, Assistant Director of Technology and Business Development at the Center for Biotechnology.
Phuong Nguyen, Commercialization Fellow at the Center for Biotechnology.
Stephen Chambers, Managing Director of IndieBio in New York.
Matthew McMahon, Director of NIH’s Small Business Education and Entrepreneurial Development (SEED) Program.
Cameron Bess, Project Officer, Antibacterials Branch, Division of CBRN Medical Countermeasures, BARDA.

To learn more and register, click here.

PACCARB: Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
2020-09-09 - 2020-09-10 | Webinar
The September PACCARB meeting, held virtually, will focus on welcoming eight new liaison members and on the impact of COVID-19 and its affect on antimicrobial resistance (AMR). Topics will include presentations on the COVID-19 mortality rate due to secondary acquired infections, antibiotic stewardship practices during a pandemic, disruptions in the agricultural industry due to COVID-19 and the intersection of AMR and emergency preparedness.
This virtual public meeting is hosted by HHS and is open to the public. It will be held via webcast.The meeting can be accessed through a live webcast on the day of the meeting.
Live Webcast: www.hhs.gov/live
Click here to learn more.

BIOCOM 4th AMR Conference: SME campus (Part II) | Focus on diagnostics
2020-08-27 06:00 - 07:00 | Webinar
Moderator:

Betsy Wonderly Trainor, Alliance Director, CARB-X

Speakers:

Peter Haug – CFO & Co-Founder, Head of Business Development & Licensing, Noscendo GmbH
Piotr Gastrecki – CTO, ScopeFluidics
Rosemarie Preyer – GenID GmbH

Bacteriophage Therapy Summit
2020-08-27 - 2020-08-28 | Webinar
As the scientific community search for alternatives to broad spectrum antibiotics, phage therapy has re-emerged as a viable solution to tackle the global health challenge of anti-microbial resistance.
As such, the 2nd Bacteriophage Therapy Summit returns digitally as a dedicated platform for leaders in industry and academia to accelerate the discovery and translation of bacteriophage research into targeted therapeutics that demonstrate clinically significant results.
With a heavy translationally focused agenda including how to overcome bacterial resistance scaling-up manufacturing and showing clinical efficacy this is your opportunity to join your peers to strengthen your product development pipelines and forge collaborations to unlock the full potential of bacteriophage therapeutics.
View the full event guide for further details on speakers, content and how to join those who paving the way for bacteriophage-based therapeutics!

BIOCOM 4th AMR Conference: AMR pull incentives | Will COVID-19 speed up or slow down implementation?
2020-08-25 10:30 - 11:45 | Webinar
Moderator:

Kathy Talkington, Director Health Programs, Pew Charitable Trust

Speakers:

Colm Leonard – Clinical Advisor/Consultant, NICE
Kevin Outterson – Professor of Law & Executive Director, CARB-X
Elmar Nimmesgern – Secretariat Lead, Global AMR R&D Hub
Daniel Berman – Lead of the Global Health Team, Longitude Prize / Nesta

BIOCOM 4th AMR Conference: Business models in AMR | How to develop strategic decisions in a challenging and global AMR market
2020-08-25 09:15 - 10:15 | Webinar
Moderator:

Gökhan Batur – CEO, Polyphor Ltd

Speakers:

Peter Beyer – Senior Advisor Department of Essential Medicines & Health Products, WHO
Erin Duffy – Chief of Research & Development, CARB-X
Holger Zimmermann – CEO, AiCuris

BIOCOM 4th AMR Conference: Business models | The AMR company of the future – Which route to success
2020-08-25 07:30 - 09:00 | RI
Moderator:

Erin Duffy – Chief of Research & Development, CARB-X

Speakers:

Jonathan Butcher – Head of Business Development, BioVersys AG
Cherif Bousselham – Senior Vice President, Head of Sales, EMEA, Accelerate Diagnostics Inc.
Jean-Pierre Paccaud – Director of Business Development and Corporate Strategy, GARDP
Kenneth Bradley – Global Head, Infectious Disease Discovery, Roche

BIOCOM 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics
2020-08-24 - 2020-08-28 | Webinar
This year’s digital AMR Conference will be an international forum to discuss AMR in the context of COVID-19 and beyond.
CARB-X speakers include Kevin Outterson, Executive Director, Erin Duffy, Chief of Research and Development, and Betsy Wonderly Trainor, Alliance Director.
The current global health crisis caused by COVID-19 shows more than ever the importance of infectious diseases expertise and the high need for further fighting against antimicrobial resistance (AMR). A cross-sectoral international dialogue with all stakeholders involved will be crucial to help implement innovative therapies and diagnostics in the clinical practice globally.
Together with our supporters – among others our major partner, the BEAM Alliance – the AMR Conference will continue to provide a (virtual) platform for those debates bringing together stakeholders from industry, SMEs, start-ups, academia, clinics, investors, public institutions and policy. Within our digital AMR Conference Week in August, we want to catch up discussing the challenges of bringing new antimicrobial treatments and diagnostics into the market and as a result, help to establish a post-COVID policy roadmap on AMR.
Five days of insights and networking for the global AMR community: Each conference day will cover a focus topic with selected LIVE sessions and high-level panels. Additionally, you will be able to explore scientific poster presentations and participate in virtual 1:1 meetings throughout the whole week and to engage within our new digital AMR stakeholder platform which is currently being set up.

Click here to view the programme.
Click here to learn more.
Click here to register.

Longitude Prize Sprint Workshop 1 - Navigating MedTech Regulation Pathways in Developed and Emerging Markets
2020-08-07 10:00 - 15:00 | Webinar
In July 2020, the Longitude Prize is launching the Longitude Prize Sprint Programme. The Sprint programme is free and will consist of a mix of Sprint Workshops and Sprint 1:1 Expert Support and is perfect for people and teams working in the field of AMR diagnostic test development. The Longitude Prize will be running three Sprint Workshop webinars from July to November 2020. The Sprint Workshops (virtual webinars) are open to all Longitude Prize Competitors, along with diagnostic test developers who are looking for technical advice and support for regulatory pathways, finance and investment, and manufacture and distribution strategies.

Longitude Prize Sprint Workshop 1 – Navigating MedTech Regulation Pathways in Developed and Emerging Markets

Medtech product development and commercialisation for devices and diagnostics is a complex process and has a long gestation period. There are many uncertainties that Medtech product development has to navigate especially during technology development and validation stages of product development as well as being able to meet regulatory standards. Successful navigation of the regulatory maze is important in product development roadmap.
There are subtle and distinct variations in regulatory standards for Medtech products across different geographies especially between developed and developing countries. Another layer of complexity is the continuous change in regulatory landscapes both in mature and evolving markets across the world.
The workshop (virtual webinar), as part of the Longitude Prize Sprint programme, will draw upon insights from experts in Medtech regulation and address the nuances of regulation in different geographies which will guide Medtech companies in their product development strategies.

To learn more, click here.

Live Webinar: GARDP/REVIVE – The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study
2020-07-09 03:00 - 04:30 | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers:

Anand Anandkumar, Co-founder and CEO Bugworks Research Inc (India)
Kamini Walia, Program Officer, ICMR-AMR Initiative (India)

Moderator: François Franceschi, GARDP
In this webinar, Anand Anandkumar and Kamini Walia will discuss:

Why is India one of the hotbeds of the AMR problem? Latest statistics of growing drug resistance etc.
Initiatives of the Indian Government to curb the AMR problem
Antimicrobial R&D landscape in India – a vibrant ecosystem supporting innovation in AMR diagnosis, prevention and therapeutics
Fledgling antimicrobial clinical trial networks – could trials out of India play a significant role in gaining global regulatory approvals?
Changing regulatory environment to enable accelerated approvals for antimicrobial products

The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 5 May 2020, 9:00-10:30 am CEST (find your time zone here).

Live Webinar: GARDP/REVIVE – Clinical development of antimicrobials – Phase 1 development challenges
2020-06-30 11:00 - 12:30 | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speaker: Markus Zeitlinger, Head of Department of Clinical Pharmacology, Medical University of Vienna (Austria)
Moderator: Markus Heep
The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 30 June, 17:00-18:30 CEST. Find your time zone here.

JLABS Webinar: Raising Capital: A Legal Primer
2020-06-25 11:00 - 12:15 | Webinar
Having a clear strategy for raising growth capital and understanding the evolution and dynamic of investment deals are essential for the long-term health of your business. Join JLABS, Allen & Overy and O’Melveny to learn more and discuss key issues such as:

Key points in growth capital deals
Evolution of deal dynamics
Board seats
Governance structure
Economic terms
Exit terms

To learn more, click here.

This program is part of the Johnson & Johnson Innovation – JLABS Legal Webinar Series for life science entrepreneurs, together with Allen & Overy and O’Melveny. You can register for other webinars in the series by visiting this page.

JLABS Webinar: Pulse Check-Today's Funding Landscape
2020-06-09 12:00 - 13:00 | Webinar
Today’s current crisis has changed the mindset of many industry strategic partners, investors and overall stakeholders. From pivoting investment priorities, to identifying new areas of innovation, the investor landscape is constantly shifting.
For small to medium sized biotechs, it can be hard to keep up with promised milestones while also planning and anticipating the future of their companies. How could companies be preparing for not only the short-term but for years to come? What should be prioritized in the coming months? Who is still investing? How can they find the right partners for them as they move forward?
Join JLABS as we welcome members of Johnson and Johnson Development Corp., and other industry investors to:

Share how they are planning for the future and pivoting in the current crisis
What they believe companies should be prioritizing
How bio-techs could stay connected with their current and potential stakeholders
Where they could find the right resources and investment opportunities, and overall gain a pulse check on the investor community

To learn more, click here.

Live Webinar: GARDP/REVIVE – Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations
2020-06-09 11:00 - 12:30 | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speaker: Vincent H. Tam, Professor, University of Houston College of Pharmacy (USA)
Moderator: Shampa Das, Senior Lecturer, Centre of Excellence in Infectious Diseases Research, University of Liverpool (UK)
In this webinar, Vincent H. Tam will present on his work looking at studying PK/PD in fixed dose beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations.
Topics discussed will include:

Understanding the inherent challenges associated with PK/PD of BL/BLI combinations
Demonstrating new approaches to gain useful insights from preclinical PK/PD models

The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 9 June 2020, 17:00-18:30 CEST (find your time zone here).

Live Webinar: o2h ventures 6th ChaiTime Webinar Registration
2020-05-29 10:00 - 11:30 | Webinar
Join us on Friday, May 29 @ 3:00 PM BST (10:00 AM EST / 7.30 PM IST) for our the sixth o2h ventures ChaiTime webinar on ‘Antibiotic Resistance – The fight for humanity’.
Erin Duffy, Chief of R&D, CARB-X , will chair the 6th o2h ventures ChaiTime discussion on drug resistance and lessons to be learned fron the COVID-19 pandemic.
Click Here to Register for the Webinar.
Webinar Chair:
Erin Duffy, Chief of R&D @ CARB-X
Panelists and Speakers:
Ken Bradley, Global Head, Infectious Disease Discovery at Roche pharmaceutical Research and Early Development (pRED)
Ankit Mahadevia, CEO of NASDAQ listed, Spero Therapeutics
Paul Finn, CEO of Oxford University Spinout, Oxford Drug Design
Ajay Mistry, CEO of AI and antibiotics discovery start-up, Oppilotech

Live Webinar – CARB-X - How to Prepare for an FDA Pre-IND Meeting: Planning for Success
2020-05-28 12:00 - 13:00 | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers:
Carmella Moody, Regulatory Program Director, RTI International
Michael Bevilacqua, M.D., Ph.D., Chief Executive Officer and Chief Science Officer, Amicrobe Inc.
In this webinar, Carmella Moody and Michael Bevilacqua will help product developers understand how best to prepare for pre-IND meetings to ensure maximum results.
Carmella Moody has many years experience supporting and preparing companies for pre-IND meetings. Michael Bevilacqua, who worked with CARB-X to prepare for his company’s recent pre-IND meeting, will discuss his positive experience and lessons learned. Everyone is welcome to join. A recording of the webinar will be available for those who cannot attend the live broadcast.
Presentations will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on May 28, 12:00 to 13:00 ET (find your time zone here).

Live Webinar: GARDP/REVIVE – Assay development for measuring antibiotic accumulation in Gram-negative bacteria
2020-05-19 11:00 - 12:30 | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers:

Jessica Blair, Institute of Microbiology and Infection, University of Birmingham (UK)
Mark Brönstrup, Department of Chemical Biology, Helmholtz Centre for Infection Research (Germany)
David A. Six, Venatorx Pharmaceuticals, Inc. (US)

Moderator: Alice Erwin, Erwin Consulting LLC (US)
The presentation will be followed by a Q&A session.
Register now for this live webinar.

Live Webinar: GARDP/REVIVE – Probability of target attainment analyses for dose selection in antimicrobial drug development
2020-05-12 11:00 - 12:30 | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speaker: Shampa Das, Senior Lecturer, Centre of Excellence in Infectious Diseases Research, University of Liverpool (UK)
Moderator: Vincent H. Tam, Professor, University of Houston (US)
In this webinar, Shampa Das will give an overview of her work in studying the PK/PD and probability of target attainment for dose selection.
Topics discussed will include:

An overview of what is meant by the probability of target attainment (PTA)
How it is calculated and what data is used for this
How PTA is used for decision making during drug development

The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 12 May 2020, 17:00-18:30 CEST (find your time zone here).

Live Webinar: GARDP/REVIVE – Inhaled antimicrobials: Do we get the drug to the bug?
2020-04-28 11:00 - 12:30 | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speaker: Harm A. W. M. Tiddens, Professor of Pediatric Pulmonology and Allergology, Erasmus Medical Center Sophia Children’s Hospital (Netherlands)
Moderator: Harpal Singh Dhillon, Global Medical Value Director & Founder, AntiBx (UK)

In this webinar, Harm Tiddens will discuss the relation between structural and functional abnormalities of the lung and how this can impact upon the deposition pattern and efficacy of inhaled antibiotics. He will further present the learnings of his research group’s computational fluid dynamic modelling studies and explain why the expectation that inhaled antibiotics result in high concentrations in the lung is unfortunately a misconception.
The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 28 April, 17:00-18:30 CEST (find your time zone here).

BAARN2020: Boston Area Antimicrobial Research Network Meeting
2020-03-20 09:00 - 17:00 | Harvard Campus, 52 Oxford Street, Cambridge, MA, 02138, United States
The Boston Area Antimicrobial Resistance Network Meeting, to be held on Friday, March 20th.

BAARN2020 will be the 7th iteration of this flagship MSI event, bringing together our collective talents across academia and industry to address the persistent dilemma posed by antimicrobial resistant infection.

Talks will begin at 9 AM in the Northwest Labs Building at 52 Oxford Street, Cambridge MA 02138, and our sessions will conclude with the annual Stuart Levy Lecture. A reception will follow at 6 PM at the Harvard Museum of Natural History next door.

Live Webinar: GARDP/REVIVE - PK/PD murine infection models: Focus on study elements, variability, and interpretation of results
2020-02-27 11:00 - 12:30 | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
In this webinar, Alexander J. Lepak will review critical study elements that lead to robust preclinical PK/PD results in the murine model.
Topics discussed will include:

Understanding and embracing the inherent variability in many components of the murine model
Demonstrating how to generate and interpret preclinical murine model PK/PD results

The presentation will be followed by a Q&A session.
The material presented in this webinar was shown but not recorded at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019.
Speaker: Alexander J. Lepak, Assistant Professor, Department of Medicine, University of Wisconsin School of Medicine and Public Health (USA)
Moderator: Peter Warn, Evotec (UK)
Register here for this live webinar.

Live Webinar: GARDP/REVIVE - Non-traditional antibacterial therapeutic options and challenges
2020-02-04 11:00 - 12:30 | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
In this webinar, the following aspects will be presented:

Discovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline
These approaches include anti-virulence strategies, microbiome-modifying therapies, phages and others such as nanoparticles, immunotherapy and drug-resistance modulation
Some of these approaches require novel preclinical efficacy models to predict clinical outcome
Pathogen-specific or even patient-specific strategies dominate this field
A major challenge will be to show efficacy in clinical trials

The presentation will be followed by a Q&A session with Ursula Theuretzbacher and Laura Piddock (GARDP).
Speaker: Ursula Theuretzbacher, CEFAIA, Austria
Moderator: Prabhavathi Fernandes, Chair of GARDP’s Scientific Advisory Committee
Register here for this live webinar.

Live Webinar: GARDP/REVIVE - Testing for the potential of emergence of antimicrobial resistance
2020-01-21 11:00 - 12:30 | RI
In this webinar, the following aspects will be presented:

What are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques?
What are some techniques that may be used to understand the origins of resistance selection?
How to rationalize/manage the risk of translation of the resistance selection from in vitro to the clinical settings?

The presentation will be followed by a Q&A session.
This presentation was also part of the ‘Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process’, jointly organized by GARDP, CARB-X, REPAIR Impact Fund, JPIMAR and Wellcome Trust at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019.

Speaker: Michael Mourez, Head BacteriOmics Platform, Evotec (France)
Moderator: Laura Piddock, Director Scientific Affairs, GARDP
Register here for this live webinar.

Davos 2020 World Economic Forum - Novo Nordisk Foundation and Novo Holdings: The Broken Model of Antimicrobial resistance
2020-01-21 08:00 - 17:00 | DAVOS-KLOSTERS, Switzerland
Moderator: Kevin Outterson, Executive Director, CARB-X, Professor of Law, Boston University
Panel:

Lars Rebien Sorensen, Chairman of the Novo Nordisk Foundation and Novo Holdings
Jeremy Farrar, Director, Wellcome Trust
Dr. Malin Grape, Head of Antibiotics Unit, The Public Health Agency of Sweden
Thomas Cueni, Director General, IFPMA
Jayasree K. Iyer, Executive Director, Access to Medicine Foundation
Francesca Colombo, Head of the Health Division, OECD

Antimicrobial resistance is one of the biggest threats to human health. The Novo Nordisk Foundation is hosting a session at the World Economic Forum’s Annual Meeting in Davos urging governments, the biopharma industry and other stakeholders to step up the urgency and respond to the crisis in #antimicrobialresistance with new funding models.
To watch a recording of this panel, please click here.

Exploring Opportunities to Reform Antimicrobial Payment and Post-Market Incentives
2020-01-16 10:30 - 16:30 | Washington Marriott at Metro Center, 775 12th Street NW, Washington, DC, 20005, United States
Speakers include Kevin Outterson, Executive Director of CARB-X.
The rise of antimicrobial resistance and the corresponding lack of novel antibiotic development impacts the ability of physicians to provide appropriate care for patients. The greatest barriers to a robust antibiotic ecosystem are low return on investment (ROI) and limited market opportunities, in part due to payment decisions that don’t reflect the value of antibiotics that extends beyond the hospital stay. For years, policy makers and other stakeholders have been exploring ways to improve the antibiotic ecosystem through development, regulatory, and market incentives proposals, though to date there has been limited impact on manufacturers’ ability to generate adequate ROI.
This public meeting will highlight recent actions implemented by stakeholders in the U.S. and globally, and present additional opportunities to effect change to payment and the costs and returns to antimicrobial investment systems through legislative, administrative, and private sector mechanisms.
